Viral infectivity factor: A novel therapeutic strategy to block HIV-1 replication

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 7, 2013, Pages 1047-1055

  Yang, Guliang ^a   Xiong, Xujie ^a  

^a HUANGGANG NORMAL UNIVERSITY   (China)

Author keywords

Accessory proteins; Function; HIV 1; Inhibitors; Structure; Vif

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; BIOLOGICAL FACTOR; ELONGIN B; ELONGIN C; UNCLASSIFIED DRUG; VIRAL INFECTIVITY FACTOR;

ANTIVIRAL ACTIVITY; CELL CYCLE; CELL CYCLE PROGRESSION; CRYSTAL STRUCTURE; DNA REPAIR; GENE MUTATION; GENOME ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROGEN BOND; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN MULTIMERIZATION; PROTEIN PHOSPHORYLATION; REVIEW; VIRUS INFECTIVITY; VIRUS REPLICATION;

ANTI-HIV AGENTS; HIV-1; HUMANS; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

EID: 84878653404     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557511313070008     Document Type: Review

References (58)

1. Richter, S.N.; Frasson, I.; Palu, G. Strategies for inhibiting function of HIV-1 accessory proteins: a necessary route to AIDS therapy? Curr. Med. Chem., 2009, 16(3), 267-286.
2. Yu, M.; Li, Z.; Liu, S.; Fan, E.; Pannecouque, C.; De Clercq, E.; Liu, X. Synthesis and biologicalevaluationof6substituted5alkyl2(phenylaminocarbonylmethylthio)pyrimidin-4(3H)-ones as potent HIV-1 NNRTIs. Chem. Med. Chem., 2011, 6(5), 826-833.
3. Zhan, P.; Li, Z.; Liu, X.; De Clercq, E. Sulfanyltriazole/tetrazoles: a promising class of HIV-1 NNRTIs. Mini Rev. Med. Chem., 2009, 9(8), 1014-1023.
4. Zhan, P.; Liu, X.; Li, Z. Recent advances in the discovery and development of novel HIV-1 NNRTI platforms: 2006-2008 update. Curr. Med. Chem., 2009, 16(22), 2876-2889.
5. Stoltzfus, C.M.; Madsen, J.M. Role of viral splicing elements and cellular RNA binding proteins in regulation of HIV-1 alternative RNA splicing. Curr. HIV Res., 2006, 4(1), 43-55.
6. Exline, C.M.; Feng, Z.; Stoltzfus, C.M. Negative and positive mRNA splicing elements act competitively to regulate human immunodeficiency virus type 1 vif gene expression. J. Virol., 2008, 82(8), 3921-3931.
7. Butsch, M.; Boris-Lawrie, K. Destiny of unspliced retroviral RNA: ribosome and/or virion? J. Virol., 2002, 76(7), 3089-3094.
8. Lv, W.; Liu, Z.; Jin, H.; Yu, X.; Zhang, L. Three-dimensional structure of HIV-1 VIF constructed by comparative modeling and the function characterization analyzed by molecular dynamics simulation. Org. Biomol. Chem., 2007, 5(4), 617-626.
9. Barraud, P.; Paillart, J.C.; Marquet, R.; Tisne, C. Advances in the structural understanding of Vif proteins. Curr. HIV Res., 2008, 6(2), 91-99.
10. Kremer, M.; Schnierle, B.S. HIV-1 Vif: HIV's weapon against the cellular defense factor APOBEC3G. Curr. HIV Res., 2005, 3(4), 339-344.
11. Baraz, L.; Kotler, M. The Vif protein of human immunodeficiency virus type 1 (HIV-1): enigmas and solutions. Curr. Med. Chem., 2004, 11(2), 221-231.
12. Carr, J.M.; Davis, A.J.; Feng, F.; Burrell, C.J.; Li, P. Cellular interactions of virion infectivity factor (Vif) as potential therapeutic targets: APOBEC3G and more? Curr. Drug Targets, 2006, 7(12), 1583-1593.
13. Mezei, M.; Minarovits, J. Reversal of HIV drug resistance and novel strategies to curb HIV infection: the viral infectivity factor Vif as a target and tool of therapy. Curr. Drug Targets, 2006, 7(7), 881-885.
14. Bovolenta, C. Blocking HIV-1 Vif restores a natural mechanism of intracellular antiviral defense. Curr Drug Targets Immune Endocr Metabol Disord, 2004, 4(4), 257-263.
15. Niewiadomska, A.M.; Yu, X.F. Host restriction of HIV-1 by APOBEC3 and viral evasion through Vif. Curr. Top. Microbiol Immunol, 2009, 339(1-25.
16. Sova, P.; van Ranst, M.; Gupta, P.; Balachandran, R.; Chao, W.; Itescu, S.; McKinley, G.; Volsky, D.J. Conservation of an intact human immunodeficiency virus type 1 vif gene in vitro and in vivo. J. Virol., 1995, 69(4), 2557-2564.
17. Khan, M.A.; Aberham, C.; Kao, S.; Akari, H.; Gorelick, R.; Bour, S.; Strebel, K. Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA. J. Virol., 2001, 75(16), 7252-7265.
18. Goncalves, J.; Shi, B.; Yang, X.; Gabuzda, D. Biological activity of human immunodeficiency virus type 1 Vif requires membrane targeting by C-terminal basic domains. J. Virol., 1995, 69(11), 7196-7204.
19. Tian, C.; Yu, X.; Zhang, W.; Wang, T.; Xu, R.; Yu, X.F. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J. Virol., 2006, 80(6), 3112-3115.
20. Schrofelbauer, B.; Senger, T.; Manning, G.; Landau, N.R. Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. J. Virol., 2006, 80(12), 5984-5991.
21. Russell, R.A.; Pathak, V.K. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J. Virol., 2007, 81(15), 8201-8210.
22. Mehle, A.; Wilson, H.; Zhang, C.; Brazier, A.J.; McPike, M.; Pery, E.; Gabuzda, D. Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. J. Virol., 2007, 81(23), 13235-13241.
23. Fujita, M.; Akari, H.; Sakurai, A.; Yoshida, A.; Chiba, T.; Tanaka, K.; Strebel, K.; Adachi, A. Expression of HIV-1 accessory protein Vif is controlled uniquely to be low and optimal by proteasome degradation. Microbes Infect, 2004, 6(9), 791-798.
24. Xiao, Z.; Ehrlich, E.; Yu, Y.; Luo, K.; Wang, T.; Tian, C.; Yu, X.F. Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology, 2006, 349(2), 290-299.
25. Mehle, A.; Thomas, E.R.; Rajendran, K.S.; Gabuzda, D. A zinc-binding region in Vif binds Cul5 and determines cullin selection. J. Biol. Chem., 2006, 281(25), 17259-27265.
26. Xiao, Z.; Ehrlich, E.; Luo, K.; Xiong, Y.; Yu, X.F. Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G. FASEB J., 2007, 21(1), 217-222.
27. Yu, Y.; Xiao, Z.; Ehrlich, E.S.; Yu, X.; Yu, X.F. Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev., 2004, 18(23), 2867-2872.
28. Simon, J.H.; Sheehy, A.M.; Carpenter, E.A.; Fouchier, R.A.; Malim, M.H. Mutational analysis of the human immunodeficiency virus type 1 Vif protein. J. Virol., 1999, 73(4), 2675-2681.
29. Yu, X.; Yu, Y.; Liu, B.; Luo, K.; Kong, W.; Mao, P.; Yu, X.F. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science, 2003, 302(5647), 1056-1060.
30. Yang, B.; Gao, L.; Li, L.; Lu, Z.; Fan, X.; Patel, C.A.; Pomerantz, R.J.; DuBois, G.C.; Zhang, H. Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. J. Biol. Chem., 2003, 278(8), 6596-6602.
31. Miller, J.H.; Presnyak, V.; Smith, H.C. The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G. Retrovirology, 2007, 4(81.
32. Yang, X.; Goncalves, J.; Gabuzda, D. Phosphorylation of Vif and its role in HIV-1 replication. J Biol Chem, 1996, 271(17), 10121-10129.
33. Yang, X.; Gabuzda, D. Mitogen-activated protein kinase phosphorylates and regulates the HIV-1 Vif protein. J. Biol. Chem., 1998, 273(45), 29879-29887.
34. Stanley, B.J.; Ehrlich, E.S.; Short, L.; Yu, Y.; Xiao, Z.; Yu, X.F.; Xiong, Y. Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly. J. Virol., 2008, 82(17), 8656-8663.
35. Sheehy, A.M.; Gaddis, N.C.; Choi, J.D.; Malim, M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature, 2002, 418(6898), 646-650.
36. Zhang, L.; Saadatmand, J.; Li, X.; Guo, F.; Niu, M.; Jiang, J.; Kleiman, L.; Cen, S. Function analysis of sequences in human APOBEC3G involved in Vif-mediated degradation. Virology, 2008, 370(1), 113-121.
37. Greene, W.C.; Debyser, Z.; Ikeda, Y.; Freed, E.O.; Stephens, E.; Yonemoto, W.; Buckheit, R.W.; Esté, J.A.; Cihlar, T. Novel targets for HIV therapy. Antiviral research, 2008, 80(3), 251-265.
38. Huthoff, H.; Malim, M.H. Cytidine deamination and resistance to retroviral infection: towards a structural understanding of the APOBEC proteins. Virology, 2005, 334(2), 147-153.
39. Mbisa, J.L.; Barr, R.; Thomas, J.A.; Vandegraaff, N.; Dorweiler, I.J.; Svarovskaia, E.S.; Brown, W.L.; Mansky, L.M.; Gorelick, R.J.; Harris, R.S. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J. Virol., 2007, 81(13), 7099-7110.
40. Donahue, J.P.; Vetter, M.L.; Mukhtar, N.A.; D'Aquila, R.T. The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation. Virology, 2008, 377(1), 49-53.
41. Sadler, H.A.; Stenglein, M.D.; Harris, R.S.; Mansky, L.M. APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J. Virol, 2010, 84(14), 7396-7404.
42. Goila-Gaur, R.; Strebel, K. HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology, 2008, 5(51), 1-28.
43. Fisher, A.G.; Ensoli, B.; Ivanoff, L.; Chamberlain, M.; Petteway, S.; Ratner, L.; Gallo, R.C.; Wong-Staal, F. The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science, 1987, 237(4817), 888-893.
44. Cullen, B.R. Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J. Virol., 2006, 80(3), 1067-1076.
45. Jager, S.; Kim, D.Y.; Hultquist, J.F.; Shindo, K.; LaRue, R.S.; Kwon, E.; Li, M.; Anderson, B.D.; Yen, L.; Stanley, D.; Mahon, C.; Kane, J.; Franks-Skiba, K.; Cimermancic, P.; Burlingame, A.; Sali, A.; Craik, C.S.; Harris, R.S.; Gross, J.D.; Krogan, N.J. Vif hijacks CBF-beta to degrade APOBEC3G and promote HIV-1 infection. Nature, 2012, 481(7381), 371-375.
46. Hultquist, J.F.; Binka, M.; LaRue, R.S.; Simon, V.; Harris, R.S. Vif proteins of human and simian immunodeficiency viruses require cellular CBFbeta to degrade APOBEC3 restriction factors. J. Virol., 2012, 86(5), 2874-2877.
47. Sakai, K.; Dimas, J.; Lenardo, M.J. The Vif and Vpr accessory proteins independently cause HIV-1-induced T cell cytopathicity and cell cycle arrest. Proc. Natl. Acad. Sci. U.S.A, 2006, 103(9), 3369-3374.
48. Wang, J.; Shackelford, J.M.; Casella, C.R.; Shivers, D.K.; Rapaport, E.L.; Liu, B.; Yu, X.F.; Finkel, T.H. The Vif accessory protein alters the cell cycle of human immunodeficiency virus type 1 infected cells. Virology, 2007, 359(2), 243-252.
49. Izumi, T.; Io, K.; Matsui, M.; Shirakawa, K.; Shinohara, M.; Nagai, Y.; Kawahara, M.; Kobayashi, M.; Kondoh, H.; Misawa, N.; Koyanagi, Y.; Uchiyama, T.; Takaori-Kondo, A. HIV-1 viral infectivity factor interacts with TP53 to induce G2 cell cycle arrest and positively regulate viral replication. Proc. Natl. Acad. Sci. U.S.A, 2010, 107(48), 20798-20803.
50. Wang, J.; Reuschel, E.L.; Shackelford, J.M.; Jeang, L.; Shivers, D.K.; Diehl, J.A.; Yu, X.F.; Finkel, T.H. HIV-1 Vif promotes the G- to S-phase cell-cycle transition. Blood, 2011, 117(4), 1260-1269.
51. Li, Z.; Zhan, P.; Liu, X. 1,3,4-oxadiazole: a privileged structure in antiviral agents. Mini Rev Med Chem, 2011, 11(13), 1130-1142.
52. Nowotny, B.; Schneider, T.; Pradel, G.; Schirmeister, T.; Rethwilm, A.; Kirschner, M. Inducible APOBEC3G-Vif double stable cell line as a high-throughput screening platform to identify antiviral compounds. Antimicrob Agents Chemother, 2010, 54(1), 78-87.
53. Zhan, P.; Liu, X.; Fang, Z.; Li, Z.; Pannecouque, C.; De Clercq, E. Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Eur. J. Med. Chem., 2009, 44(11), 4648-4653.
54. Wang, X.; Zhang, J.; Huang, Y.; Wang, R.; Zhang, L.; Qiao, K.; Li, L.; Liu, C.; Ouyang, Y.; Xu, W.; Zhang, Z.; Shao, Y.; Jiang, S.; Ma, L.; Liu, J. Design, Synthesis, and Biological Evaluation of 1-[(2-Benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with an Improved Drug Resistance Profile. J. Med. Chem., 2012, 55(5), 2242-2250.
55. Luo, K.; Xiao, Z.; Ehrlich, E.; Yu, Y.; Liu, B.; Zheng, S.; Yu, X.F. Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc. Natl. Acad. Sci. U.S.A., 2005, 102(32), 11444-11449.
56. Rana, T.M., Composition and synthesis of new reagents for inhibition of HIV replication. 2007; Vol. WO2007044565.
57. Nathans, R.; Cao, H.; Sharova, N.; Ali, A.; Sharkey, M.; Stranska, R.; Stevenson, M.; Rana, T.M. Small-molecule inhibition of HIV-1 Vif. Nat. Biotechnol., 2008, 26(10), 1187-1192.
58. Zuo, T.; Liu, D.; Lv, W.; Wang, X.; Wang, J.; Lv, M.; Huang, W.; Wu, J.; Zhang, H.; Jin, H.; Zhang, L.; Kong, W.; Yu, X. Small-Molecule Inhibition of Human Immunodeficiency Virus Type 1 Replication by Targeting of the Interaction between Vif and ElonginC. J. Virol., 2012, 86(10), 5497-5507.